Wegovy, a higher-dose version of semaglutide, was approved in 2021 for weight loss in people with obesity or overweight with obesity-related conditions like high blood pressure ( hypertension ) and high cholesterol
Mounjaro (tirzepatide) and other GLP-1 receptor agonists, including Wegovy (semaglutide), can produce the same effect
The biochemical and histopathological results were compared between the 3 groups
doi: 10.1055/s-0039-1683996 9 ZhengYHuangYXuYSangLLiuXLiY
doi:10.1016/j.fertnstert.2003.10.034
In selection of therapy and combination of antihyperglycaemic medications, their effects on non-glycaemic parameters (mortality, cardiovascular or renal risk, body weight, risk of hypoglycaemia, lipid profile, etc.) should be taken into consideration while following the principle of personalisation of treatment